Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: TheSlowLane who wrote (921)	1/19/1999 11:48:00 AM
From: jopawa	Read Replies (1) \| Respond to of 2539

MTC was trading just shy of 44 when the news broke on the heart drug. They've blown out 3.6 Bil of the market cap of the co. because of that? This was hardly unexpected after the warnings last fall. We'll just have to see where we go from here. John

To: TheSlowLane who wrote (921)	1/19/1999 11:53:00 AM
From: jopawa	Respond to of 2539

11:37 [DKB,MTC] DEKALB GENETICS GETS LICENSE TO MAKE CORN THAT COULD COMBAT POULTRY VIRUS.

To: TheSlowLane who wrote (921)	1/19/1999 11:58:00 AM
From: jopawa	Respond to of 2539

Therapeutic Antibodies Says Monsanto Unit Ends Development Pact Therapeutic Antibodies Says Monsanto Unit Ends Development Pact London, Jan. 19 (Bloomberg) -- Therapeutic Antibodies Inc., an Anglo-American drug company, said Monsanto Co.'s G.D. Searle & Co. unit canceled an agreement to develop antibodies using TAB technology after Searle dropped development of two heart drugs. Therapeutic Antibodies, based in Nashville, Tenn., called the cancellation of the project ''a disappointment.'' Searle, Monsanto's drug-development division, said Jan. 15 that it ended development of xemilofiban and orbofiban. The drugs are part of a class called glycocprotein 2b/3a inhibitors and are aimed at reducing the risk of dangerous blood clots in heart- attack patients. ''While Searle's decision to stop work on their underlying projects is a disappointment, the alliance was a significant endorsement of our platform technology,'' said Andrew Heath, TAB's chief executive. TAB shares dropped 1 penny to 53.5p in London. -Dane Hamilton in the London newsroom (44-171) 330-7727/ab Story illustration: TAB LN GP for a chart of share performance. Company news: TAB LN CN Therapeutic Antibodies MTC US CN Monsanto News by Category: NI DRG Drugs NI BTC Biotechnology NI COS Companies NI UKX U.K. Stocks For news on people mentioned in this story, type WHO, then name of person, then . Regional News: NI UK United Kingdom NI EUROP Europe NI US United States NI TN Tennessee NI MO Missouri TNI UK DRG for more news about the U.K. drug business. TOP UK for the latest top stories in the U.K.